Novartis AG Statistics
Total Valuation
Novartis AG has a market cap or net worth of $292.60 billion. The enterprise value is $317.42 billion.
Important Dates
The last earnings date was Wednesday, February 4, 2026, before market open.
| Earnings Date | Feb 4, 2026 |
| Ex-Dividend Date | Mar 12, 2025 |
Share Statistics
Novartis AG has 1.91 billion shares outstanding. The number of shares has decreased by -3.86% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.91B |
| Shares Change (YoY) | -3.86% |
| Shares Change (QoQ) | -0.57% |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 37.13% |
| Float | 1.82B |
Valuation Ratios
The trailing PE ratio is 21.53 and the forward PE ratio is 17.12.
| PE Ratio | 21.53 |
| Forward PE | 17.12 |
| PS Ratio | 5.16 |
| Forward PS | 5.10 |
| PB Ratio | 6.29 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 16.63 |
| P/OCF Ratio | 15.28 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 14.34, with an EV/FCF ratio of 18.04.
| EV / Earnings | 22.70 |
| EV / Sales | 5.60 |
| EV / EBITDA | 14.34 |
| EV / EBIT | 17.99 |
| EV / FCF | 18.04 |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.12 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | 2.02 |
| Interest Coverage | 15.42 |
Financial Efficiency
Return on equity (ROE) is 30.81% and return on invested capital (ROIC) is 21.92%.
| Return on Equity (ROE) | 30.81% |
| Return on Assets (ROA) | 10.34% |
| Return on Invested Capital (ROIC) | 21.92% |
| Return on Capital Employed (ROCE) | 21.09% |
| Weighted Average Cost of Capital (WACC) | 6.33% |
| Revenue Per Employee | $752,973 |
| Profits Per Employee | $185,792 |
| Employee Count | 75,267 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.28 |
Taxes
In the past 12 months, Novartis AG has paid $2.39 billion in taxes.
| Income Tax | 2.39B |
| Effective Tax Rate | 14.59% |
Stock Price Statistics
The stock price has increased by +45.97% in the last 52 weeks. The beta is 0.46, so Novartis AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +45.97% |
| 50-Day Moving Average | 139.54 |
| 200-Day Moving Average | 125.83 |
| Relative Strength Index (RSI) | 70.50 |
| Average Volume (20 Days) | 2,055,676 |
Short Selling Information
The latest short interest is 5.65 million, so 0.29% of the outstanding shares have been sold short.
| Short Interest | 5.65M |
| Short Previous Month | 5.42M |
| Short % of Shares Out | 0.29% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.85 |
Income Statement
In the last 12 months, Novartis AG had revenue of $56.67 billion and earned $13.98 billion in profits. Earnings per share was $7.15.
| Revenue | 56.67B |
| Gross Profit | 42.98B |
| Operating Income | 17.64B |
| Pretax Income | 16.35B |
| Net Income | 13.98B |
| EBITDA | 22.13B |
| EBIT | 17.64B |
| Earnings Per Share (EPS) | $7.15 |
Full Income StatementBalance Sheet
The company has $11.59 billion in cash and $35.46 billion in debt, with a net cash position of -$23.87 billion or -$12.48 per share.
| Cash & Cash Equivalents | 11.59B |
| Total Debt | 35.46B |
| Net Cash | -23.87B |
| Net Cash Per Share | -$12.48 |
| Equity (Book Value) | 46.55B |
| Book Value Per Share | 24.11 |
| Working Capital | 3.18B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $19.14 billion and capital expenditures -$1.55 billion, giving a free cash flow of $17.60 billion.
| Operating Cash Flow | 19.14B |
| Capital Expenditures | -1.55B |
| Free Cash Flow | 17.60B |
| FCF Per Share | $9.20 |
Full Cash Flow StatementMargins
Gross margin is 75.83%, with operating and profit margins of 31.13% and 24.67%.
| Gross Margin | 75.83% |
| Operating Margin | 31.13% |
| Pretax Margin | 28.85% |
| Profit Margin | 24.67% |
| EBITDA Margin | 39.05% |
| EBIT Margin | 31.13% |
| FCF Margin | 31.05% |
Dividends & Yields
This stock pays an annual dividend of $2.60, which amounts to a dividend yield of 1.69%.
| Dividend Per Share | $2.60 |
| Dividend Yield | 1.69% |
| Dividend Growth (YoY) | 6.80% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 36.31% |
| Buyback Yield | 3.86% |
| Shareholder Yield | 5.54% |
| Earnings Yield | 4.78% |
| FCF Yield | 6.01% |
Dividend DetailsAnalyst Forecast
The average price target for Novartis AG is $118.00, which is -23.35% lower than the current price. The consensus rating is "Hold".
| Price Target | $118.00 |
| Price Target Difference | -23.35% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 4.07% |
| EPS Growth Forecast (5Y) | 11.36% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on May 11, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | May 11, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |
